Editorial · 29 Mar 2021
EditorialPublished 25 Jan 2021
Editor Note on Diabetes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
ARCHIL K The worldwide obesity treatment showcase is relied upon to achieve USD 15.6 billion by 2024, as indicated by another report by Grand View Research, Inc. Upward pattern in stationary ways of life, physical inertia, and unfortunate sustenance propensities are the key variables in charge of the high predominance of obesity. As indicated by the Institute of Health Metrics and Evaluation, around 30.0% of the worldwide populace is either obese or overweight. Furthermore, alongside business accessibility of answers for weight administration, innovative progressions presented by the vertical players and steady activities embraced by the legislatures, make more mindfulness as to corpulence and its effect on wellbeing. This is further driving the development of the corpulence treatment showcase. There are different methodologies for weight administration, for example, eat less, work out, drugs, insignificantly obtrusive gadgets and inserts, and surgeries. Among the common medications, the blend drugs hold the biggest piece of the pie though satiety tranquilizes that provide a sentiment totality show up as the quickest developing portion in the weight treatment showcase. The world over, the high obesity rate has become a burden, and the dire need to bring it under control has risen as a result. World Health Organization (WHO) suggests that over 50% of the worldwide population is obese. Furthermore, in the year 2014, over 1.9 billion adults that were 18 years and above were overweight. Out of these, more than 600 million were reported obese. Obesity is connected to various chronic diseases, including hypertension, orthopedic disorders, diabetes, and cancer. At present, numerous solutions including exercise, diet, minimally invasive devices & implants, invasive surgeries, and drugs, are available to manage weight. Obesity refers to a multifactorial disease that involves several genetic as well as physiological factors contributing to disease progression. As the results of monotherapy are limited; a holistic approach to achieve effective obesity control has become necessary. Owing to this, a combination of drugs finds widespread use in the treatment of obesity. Successful clinical trials and the consequent emergence of advanced and innovative products like satiety drugs are projected to create growth opportunities for the market in the following years. Gastric bypass procedure is considered the most popular bariatric surgery, followed by minimally invasive procedures. Shorter hospital stays, cost-effectiveness, and speedy recovery are few prominent factors elevating the demand for minimally invasive surgeries. Additionally, government initiatives with the aim of augmenting the adoption rate of minimally invasive surgeries to decrease the incidence of hospital-acquired infections, as well as hospital readmissions, will stimulate market growth as well. Obesity Treatment Market Players: The prominent vendors competing in the worldwide obesity treatment market include Olympus Corporation (Japan), F. Hoffmann-La Roche, Ltd. (Switzerland), Cousin Biotech (France), VIVUS, Inc. (U.S.), Allergan (Republic of Ireland), Johnson & Johnson Services, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), Orexigen Therapeutics, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Covidien plc (Republic of Ireland), Mediflex Surgical Products (U.S.), EnteroMedics, Inc. (U.S.), Novo Nordisk A/S (Denmark), and others. Obesity Treatment Market Segmentation: The global market for obesity treatment can be segmented based on type, diagnosis, treatment and Prevention, end-user. With respect to the type, the market is considered for inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. Depending on the diagnosis, the market is categorized based on blood tests, physical examination, and others. The blood tests segment is further divided into cholesterol test, liver function test, thyroid test, and others. The physical examination segment caters to heart rate measurement, blood pressure measurement, and others. Treatment-wise segments in the market are medication, surgery, lifestyle changes, and others. The medication segment can be broken down into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment covers into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. The end-users covered by the report are hospitals, clinics, pharmacies, and others.
Keywords
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 29 Mar 2021
Editor Note on Gestational Diabetes Mellitus
Editorial · 29 Mar 2021
Editor Note on Neonatal Diabetes Mellitus
Editorial · 31 Jan 2021
Editor Note Diabetes Management
Editorial · 25 Jan 2021
Editor Note For Diabetes Management
More from this journal
The newest in Diabetes Management.
Article · 28 Oct 2025
Glucose control in older adults with diabetes following intra-articular and epidural triamcinolone acetonide injections
Article · 22 Jan 2025
Lipodystrophy with an uncommon clinical presentation in a patient with type 2 diabetes on insulin therapy
Article · 22 Jan 2025
Lipodystrophy with an uncommon clinical presentation in a patient with type 2 diabetes on insulin therapy
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDiabetes Management
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “ARCHIL K”
